Squamous cell carcinoma of mouth
Item
histologically or cytologically proven squamous cell carcinoma of the oral cavity.
boolean
C0585362 (UMLS CUI [1])
Primary tumor site Oral cavity | Chemotherapy | Neoplasm of nasal cavity Excluded | Nasal sinus Neoplasms Excluded | Nasopharyngeal Neoplasms Excluded | Mouth Neoplasms Associated with Mandible Invasion | Excision Probably
Item
primary tumor sites eligible: oral cavity. although they are admittedly of squamous cell types, the following tumors will be excluded because their responsiveness to chemotherapy may differ: tumors of the nasal and paranasal cavities and of the nasopharynx. oral cavity tumors with mandible invasion are excluded because the tumor biology and management of these tumors is more complex and will likely include upfront surgical resection.
boolean
C0475447 (UMLS CUI [1,1])
C0226896 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C0345630 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
C0030471 (UMLS CUI [4,1])
C0027651 (UMLS CUI [4,2])
C2828389 (UMLS CUI [4,3])
C0027439 (UMLS CUI [5,1])
C2828389 (UMLS CUI [5,2])
C0026640 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C0024687 (UMLS CUI [6,3])
C1269955 (UMLS CUI [6,4])
C0728940 (UMLS CUI [7,1])
C0750492 (UMLS CUI [7,2])
Disease TNM clinical staging | Distant metastasis Absent Plain chest X-ray | Distant metastasis Absent Ultrasonography of abdomen | Liver function tests abnormal X-Ray Computed Tomography | Symptoms Local Bone scan
Item
stage 3 or 4 disease without evidence of distant metastases verified by chest x-ray, abdominal ultrasound, or ct scan (liver function test abnormalities); bone scan in case of local symptoms.
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C1302548 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0039985 (UMLS CUI [2,3])
C1302548 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0203464 (UMLS CUI [3,3])
C0151766 (UMLS CUI [4,1])
C0040405 (UMLS CUI [4,2])
C1457887 (UMLS CUI [5,1])
C0205276 (UMLS CUI [5,2])
C0203668 (UMLS CUI [5,3])
Measurable lesion Linear Quantity | Measurable lesion 2-Dimensional Quantity
Item
at least one uni- or bi-dimensionally measurable lesion.
boolean
C1513041 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1513041 (UMLS CUI [2,1])
C1705052 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Age
Item
age ≥ 18 years.
boolean
C0001779 (UMLS CUI [1])
WHO performance status scale
Item
who (world health organization)performance status of 2 or less.
boolean
C1298650 (UMLS CUI [1])
Chronic Alcoholic Intoxication Absent
Item
no active alcohol addiction.
boolean
C0001973 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Clinical Trial Eligibility Criteria Determination Final
Item
final eligibility for a clinical trial is determined by the health professionals conducting the trial.
boolean
C1516637 (UMLS CUI [1,1])
C0013893 (UMLS CUI [1,2])
C3853528 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Malignant Neoplasms Site Other | Carcinoma in situ of uterine cervix Treated | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated | Curative Surgery Malignant Neoplasms | Disease Free of
Item
previous malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal, or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years.
boolean
C0006826 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0851140 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0007117 (UMLS CUI [3,1])
C1522326 (UMLS CUI [3,2])
C0553723 (UMLS CUI [4,1])
C1522326 (UMLS CUI [4,2])
C1511562 (UMLS CUI [5,1])
C0006826 (UMLS CUI [5,2])
C0012634 (UMLS CUI [6,1])
C0332296 (UMLS CUI [6,2])
Therapeutic radiology procedure | Chemotherapy
Item
any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
Weight decreased Involuntary Percentage
Item
patients who experience an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry.
boolean
C1262477 (UMLS CUI [1,1])
C2986385 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
cancer treatment
Item
concurrent treatment with any other anti-cancer therapy.
boolean
C0920425 (UMLS CUI [1])
Participation Clinical Trial Investigational
Item
participation in an investigational trial within 30 days of study entry.
boolean
C0679823 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C1517586 (UMLS CUI [1,3])
Hypersensitivity Severe Taxotere | Hypersensitivity Severe Polysorbate 80 Drug Formulation
Item
patients with a history of severe hypersensitivity reaction to taxotere® or other drugs formulated with polysorbate 80.
boolean
C0020517 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0699967 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0032601 (UMLS CUI [2,3])
C0524527 (UMLS CUI [2,4])
Chemotherapy | Therapeutic radiology procedure | Operative Surgical Procedures Squamous cell carcinoma of the head and neck | Biopsy Excluded
Item
no previous chemotherapy or radiotherapy for any reason and no previous surgery for scchn [squamous cell carcinoma of the head and neck] (other than biopsy) are allowed at the time of study entry.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0543467 (UMLS CUI [3,1])
C1168401 (UMLS CUI [3,2])
C0005558 (UMLS CUI [4,1])
C2828389 (UMLS CUI [4,2])
Clinical Trial Eligibility Criteria Determination Final
Item
final eligibility for a clinical trial is determined by the health professionals conducting the trial.
boolean
C1516637 (UMLS CUI [1,1])
C0013893 (UMLS CUI [1,2])
C3853528 (UMLS CUI [1,3])